Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud is the lead sponsor of 19 current clinical trials in our Spain and EU (CTIS) registers. 13 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Levothyroxine and Omalizumab. The most-studied condition is Patients With Home Parenteral Nutrition.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Chronobiology and Home Parenteral Nutrition Study. CHRONO-HPN Study
NCT07554703 · ClinicalTrials.gov ↗ · Patients With Home Parenteral Nutrition
|
Not applicable | Recruiting | 2025-08 | Spain |
|
The Cooling Sensation Safe Deglution Study
NCT06936501 · ClinicalTrials.gov ↗ · Neuromotor Dysphagia After Acute Stroke
|
Not applicable | Recruiting | 2025-05 | Spain |
|
Single-cell Immune Response to Controlled Gluten Ingestion in Pediatric Celiac Disease
NCT07362654 · ClinicalTrials.gov ↗ · Celiac Disease, Gluten Sensitivity, Autoimmune Diseases
|
Not applicable | Recruiting | 2025-07 | Spain |
|
Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity.
NCT07332273 · ClinicalTrials.gov ↗ · Obesity
Drug: Levothyroxine |
Phase 3 | Recruiting | 2025-11 | Spain |
|
NIMA-Colon Cancer Study
NCT07534852 · ClinicalTrials.gov ↗ · Colon Cancer
|
Not applicable | Recruiting | 2025-07 | Spain |
|
Pectin Intervention Study and Long-term Follow-up in Lipid Transfer Proteins Allergic Patients
NCT06558526 · ClinicalTrials.gov ↗ · Food Allergy
|
Not applicable | Recruiting | 2025-01 | Spain |
|
Optimize Risk Prediction After Myocardial Infarction: The ORACLE Study
NCT06993415 · ClinicalTrials.gov ↗ · Myocardial Infarction (MI)
|
Observational | Recruiting | 2025-06 | Spain |
|
Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): A Mechanistic Study
NCT06852014 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Adult, Cephalic Duodenopancreatectomy
|
Not applicable | Recruiting | 2025-05 | Spain |
|
The Role of Breast Milk Neutrophils From Mothers With Metabolic Diseases After Nutritional Intervention. Impact on Infant Development and Response to Pulmonary Infections
NCT06833554 · ClinicalTrials.gov ↗ · Gestational Diabetes Mellitus (GDM)
|
Not applicable | Recruiting | 2023-01 | Spain |
|
SucroMet Nutritional Intervention Trial
NCT07656298 · ClinicalTrials.gov ↗ · Overweight , Obesity, Glucose Metabolism
|
Not applicable | Recruiting | 2026-07 | Spain |
|
Dietary Approaches for the Management of Overweight and Obesity in Type 1 Diabetes
NCT07667504 · ClinicalTrials.gov ↗ · Type 1 Diabetes (T1D), Obesity & Overweight
|
Not applicable | Recruiting | 2026-07 | Spain |
|
Chronobiology and Enteral Nutrition
NCT07554716 · ClinicalTrials.gov ↗ · Hospitalised Patients With Enteral Nutrition
|
Not applicable | Recruiting | 2025-10 | Spain |
|
Mentalizing and Epistemic Trust in Patients With Anxiety and Depression.
NCT06833567 · ClinicalTrials.gov ↗ · Anxiety Disorders, Depression
|
Not applicable | Recruiting | 2024-04 | Spain |
|
Endophenotyping for Plant-based Food Allergy Diagnosis, Tolerance Biomarkers, and Mechanisms in Microneedle Immunotherapy
NCT06997432 · ClinicalTrials.gov ↗ · Food Allergies
|
Observational | Not yet open | 2025-06 | Spain |
|
Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
NCT07684248 · ClinicalTrials.gov ↗ · Type 1 Diabetes
|
Not applicable | Not yet open | 2026-09 | Spain |
|
Telerehabilitation in Pulmonary Arterial Hypertension
NCT07799675 · ClinicalTrials.gov ↗ · Pulmonary Arterial Hypertension (PAH)
|
Not applicable | Not yet open | 2026-08 | Spain |
|
Sarcopenia Screening in Advanced Coxarthrosis: The SARCO-COX Study
NCT07734129 · ClinicalTrials.gov ↗ · Sarcopenia, Coxarthrosis
|
Not applicable | Not yet open | 2026-11 | Spain |
|
Implementing Online Mental Health Program
NCT07066943 · ClinicalTrials.gov ↗ · Stress, Healthcare Workers, Mindfulness
|
Not applicable | Not yet open | 2025-11 | Spain |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
Omalizumab for monotherapy treatment of patients with food allergies to plant-based foods due to sensitization to LTP and profilin
2025-524629-42-00 · CTIS ↗ · Not possible to specify
Drug: Omalizumab |
Phase 2 | Authorised | Spain |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Spain | 18 | 13 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers.
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud is the lead sponsor of 18 current trials on ClinicalTrials.gov in our Spain register, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 13 of its 18 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 2 drugs and biologicals as interventions. The most frequent are Levothyroxine (1) and Omalizumab (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.